Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin.

ABSTRACT:

Background

Psoriasis is a chronic inflammatory skin disorder involving marked immunological changes. IL-17-targeting biologics have been successful in reducing the disease burden of psoriasis patients with moderate-to-severe disease. Unfortunately, the stratum corneum prevents penetration of large molecule weight proteins, including monoclonal antibodies. Thus, for the majority of psoriasis patients ineligible for systemic treatments, a small molecule targeting RORγt, the master regulator of IL-17 family cytokines, may represent an alternative topical medicine with biologic-like efficacy.

Methods and findings

The preclinical studies described in this manuscript bridge the gap from bench to bedside to provide the scientific foundation for a compound entering clinical trials f

SUBMITTER: Smith SH 

PROVIDER: S-EPMC4752338 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature